Results 21 to 30 of about 1,816 (169)

Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b. [PDF]

PLoS ONE, 2016
BACKGROUND:Decreased hemoglobin (Hb) level has been supposed to be a relatively rare side effect of a combination therapy against hepatitis C virus that consists of the NS5A inhibitor daclatasvir (DCV) and the NS3/4A protease inhibitor asunaprevir (ASV).
Nobuyuki Matsumoto, Hiroki Ikeda, Ryuta Shigefuku, Nobuhiro Hattori, Tsunamasa Watanabe, Kotaro Matsunaga, Tetsuya Hiraishi, Tomohiro Tamura, Yohei Noguchi, Yasunobu Fukuda, Toshiya Ishii, Chiaki Okuse, Akira Sato, Michihiro Suzuki, Fumio Itoh   +14 more
doaj   +2 more sources

Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study [PDF]

Clinical and Molecular Hepatology, 2017
Background/Aims The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies.
Byeong Wook Cho, Seok Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae   +9 more
doaj   +2 more sources

Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure. [PDF]

PLoS ONE, 2016
We aimed to clarify the characteristics of resistance-associated substitutions (RASs) after treatment failure with NS5A inhibitor, daclatasvir (DCV) in combination with NS3/4A inhibitor, asunaprevir (ASV), in patients with chronic hepatitis C virus ...
Jun Itakura, Masayuki Kurosaki, Chitomi Hasebe, Yukio Osaki, Kouji Joko, Hitoshi Yagisawa, Shinya Sakita, Hiroaki Okushin, Takashi Satou, Hiroyuki Hisai, Takehiko Abe, Keiji Tsuji, Takashi Tamada, Haruhiko Kobashi, Akeri Mitsuda, Yasushi Ide, Chikara Ogawa, Syotaro Tsuruta, Kouichi Takaguchi, Miyako Murakawa, Yasuhiro Asahina, Nobuyuki Enomoto, Namiki Izumi   +22 more
doaj   +2 more sources

Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection [PDF]

Clinical and Molecular Hepatology, 2016
Background/Aims: The treatment strategy for hepatitis C virus (HCV) has been changing rapidly since the introduction of direct-acting antivirals such as daclatasvir (DCV) and asunaprevir (ASV).
Hee Chul Nam, Hae Lim Lee, Hyun Yang, Myeong Jun Song   +3 more
doaj   +2 more sources

Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions

Journal of the Formosan Medical Association, 2019
Background/Purpose: Treatment with daclatasvir plus asunaprevir (DCV + ASV) for 24 weeks provided a sustained virologic response (SVR) rate of over 90% in hepatitis C virus genotype 1b (HCV-1b) infected patients without non-structural 5A (NS5A ...
Ming-Lung Yu, Chao-Hung Hung, Yi-Hsiang Huang, Cheng-Yuan Peng, Chun-Yen Lin, Pin-Nan Cheng, Rong-Nan Chien, Shih-Jer Hsu, Chen-Hua Liu, Chung-Feng Huang, Chien-Wei Su, Jee-Fu Huang, Chun-Jen Liu, Jia-Horng Kao, Wan-Long Chuang, Pei-Jer Chen, Ding-Shinn Chen   +16 more
doaj   +2 more sources

Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C

Biomedicines, 2021
The clinical significance of mac-2 binding protein glycosylation isomer (M2BPGi) levels based on virological responses due to antiviral therapy has not been fully evaluated.
Satoshi Takakusagi, Ken Sato, Kyoko Marubashi, Kazuko Kizawa, Takashi Kosone, Satoru Kakizaki, Hitoshi Takagi, Toshio Uraoka   +7 more
doaj   +2 more sources

Comparison of Interferon-Based and Interferon-Free Treatments on the Prognosis of Hepatocellular Carcinoma After Hepatitis C Virus-Sustained Virological Response: A Multicenter Study. [PDF]

Cancer Med
ABSTRACT Aim We examine the impact of interferon (IFN)‐based and IFN‐free treatment on the prognosis of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) sustained virological response (SVR). Methods Clinical information was collected on 311 cases of HCC after HCV‐SVR from 16 facilities affiliated with the Kyushu Liver Surgery Study Group ...
Itoh S, Iseda N, Yoshizumi T, Ide T, Noshiro H, Sakai H, Hisaka T, Nakashima M, Nagano H, Okabe H, Hayashi H, Miyoshi A, Kitahara K, Takami Y, Nanashima A, Kuroki T, Endo Y, Okamoto K, Kajiwara M, Sakoda M, Beppu T, Takatsuki M, Eguchi S.   +22 more
europepmc   +2 more sources

Conformational Trajectory of the Molecular Chameleon Grazoprevir From Formulation to Target-Bound. [PDF]

Chemistry
ABSTRACT Macrocycles represent a promising class of beyond‐rule‐of‐5 (bRo5) therapeutics, capable of targeting proteins traditionally considered undruggable by conventional small molecules. Macrocycles exhibit intrinsic flexibility and often display a “chameleon‐like” ability to adapt to their environment, thereby enhancing their oral bioavailability ...
Wieske LHE, Bu G, Erdélyi M, Kihlberg J, Gonen T, Danelius ER.   +5 more
europepmc   +2 more sources

Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report

BMC Nephrology, 2017
Background Direct-acting antivirals (DAAs) dramatically improve the treatment of hepatitis C virus (HCV) infections. However, the effects of DAAs on extra-hepatic manifestations such as HCV-associated glomerulonephritis, especially in cases with renal ...
Michiko Shimada, Norio Nakamura, Tetsu Endo, Hideaki Yamabe, Masayuki Nakamura, Reiichi Murakami, Ikuyo Narita, Hirofumi Tomita   +7 more
doaj   +2 more sources

Asunaprevir [PDF]

, 2020
openaire   +2 more sources